UK markets open in 22 minutes

bioMérieux S.A. (BMXMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
103.17-7.83 (-7.05%)
At close: 02:30PM EDT

bioMérieux S.A.

376 Chemin De l’Orme
Marcy l'Étoile 69280
France
33 4 78 87 20 00
https://www.biomerieux.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees13,409

Key executives

NameTitlePayExercisedYear born
Mr. Pierre BouludChief Executive Officer1.44MN/A1971
Mr. Guillaume BouhoursExecutive VP of Purchasing and Information Systems & CFON/AN/A1976
Sylvain MorgeauInvestor RelationsN/AN/AN/A
Ms. Audrey DauvetExecutive Vice President of Legal, Corporate Integrity & Public AffairsN/AN/A1974
Ms. Valerie LeyldeExecutive Vice President of Human Resources, Communications & CSRN/AN/AN/A
Mr. Pierre CharbonnierExecutive Vice President of Global Quality, Manufacturing & Supply ChainN/AN/AN/A
Mr. Yasha MitrottiExecutive Vice President of Industrial ApplicationsN/AN/AN/A
Mr. Frederic BesemeHead of CSR23.46kN/A1956
Jennifer ZinnExecutive Vice President of Clinical OperationsN/AN/AN/A
Charles K. CooperExecutive VP & Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Corporate governance

bioMérieux S.A.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.